What an AI agent reads on Aesthetic
An assistant's crawler fetches the page once, without running JavaScript, and reads the text, the structured data and the links. Below is what it gets from aestheticsadvisor.com, taken from the copy the scanner kept.
11,439
characters of text without JavaScript
Organization
structured data for the business
0
of 3 AI crawlers turned away at the edge
The words an agent gets
Title: The Aesthetics Advisor · language en. First 1,800 of 11,439 characters:
The Aesthetics Advisor Skip to main content Search This Blog The Aesthetics Advisor Independent Guides for Wellness and Beauty Home About Us E-Shop Vitamins and Supplements Anti Aging Cancer Stem Cell More… Posts Retatrutide vs Tirzepatide vs Semaglutide (Ozempic): GLP-1 Wars — Updated Review (2026) Get link Facebook X Pinterest Email Other Apps - October 08, 2026 Medically Reviewed by: Dr. Frank Yap, MD | Written by: OneDayMD Editorial Team | Published: March 2026 | Last updated: October 6, 2026 Quick Answer As of October 2026, tirzepatide (Zepbound) is the strongest FDA-approved option at about 20–21% average weight loss, ahead of semaglutide (Wegovy) at about 15% (20.7% at the new 7.2 mg dose). Retatrutide, a triple agonist, reached 28.3% at 80 weeks in Phase 3 but is not FDA-approved ; Lilly plans to file in Q1 2027. What changed in this update (Oct 2026): replaced pre-Phase-3 estimates with TRIUMPH-1/2/3 results; corrected retatrutide launch timing (not before late 2027); added Wegovy HD, the Wegovy pill, Foundayo and CagriSema context; removed claims sourced only from research-peptide vendors, forum posts and unverified preprints; added CEBM evidence tiers, FAQ and an AI-prompt guide. Contents At-a-glance comparison How the three work What the trials show (and don't) Retatrutide: status in October 2026 Muscle and lean... Post a Comment Read more Navigating "Ozempic Face," Muscle Loss, and Long-Term Maintenance: Updated Guide to GLP-1 Success (June 2026 Edition) Get link Facebook X Pinterest Email Other Apps - October 08, 2026 Quick Summary of Key Insights "Ozempic Face" is a result of rapid weight loss, not the drug itself. Up to 35-40% of weight lost can come from lean mass if not managed carefully. Gradual weight loss (1-2 pounds per week) is the gold sta
What it can say about the business
| A business type in JSON-LD | Organization |
| Name | Blogger |
| Telephone | no |
| Address | no |
| Opening hours | no |
| Menu or price list | nothing |
| Cuisine in structured data | no |
| JSON-LD blocks | 4 (BlogPosting, ImageObject, Organization, Person, WebPage) |
The links it would act on
No booking or ordering link found. An agent has nothing to act on.
Everything here comes from fetching the homepage once as a crawler. The report turns it into a score and a list of fixes, with code to paste.